SUPPLEMENT
Q1 2024 — Financial disclosures
Q1 2024PDF · 9 pages1.0 MB
Merck & Co., Inc. Financial Highlights Package First Quarter 2024 Table of Contents Table 1: GAAP P&L..........................................................................1 Table 1a: GAAP P&L – Current Year and Prior Year by Quarter......2 Table 2a: GAAP to Non-GAAP Reconciliation 1Q24.........................3 Table 2b: GAAP to Non-GAAP Reconciliation 1Q23.........................4 Table 3: Sales – Current Year and Prior Year by Quarter ...............5 Table 3a: Sales – U.S. / Ex- U.S. 1Q24.............................................6 Table 3b: Sales – Pharmaceutical Geographic Split .........................7 Table 4: Other (Income) Expense ....................................................8 -- 1 of 9 -- Sales 15,775 $ 14,487 $ 9% Costs, Expenses and Other Cost of sales 3,540 3,926 -10% Selling, general and administrative 2,483 2,479 0% Research and development 3,992 4,276 -7% Restructuring costs 123 67 84% Other (income) expense, net (33) 89 * Income Before Taxes 5,670 3,650 55% Income Tax Provision 903 825 Net Income 4,767 2,825 69% Less: Net Income Attributable to Noncontrolling Interests 5 4 Net Income Attributable to Merck & Co., Inc. 4,762 $ 2,821 $ 69% Earnings per Common Share Assuming Dilution 1.87 $ 1.11 $ 68% Average Shares Outstanding Assuming Dilution 2,544 2,551 Tax Rate 15.9% 22.6% * 100% or greater MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1 GAAP % Change 1Q24 1Q23 1 -- 2 of 9 -- Sales 15,775 $ 14,487 $ 15,035 $ 15,962 $ 14,630 $ 60,115 $ 9% Costs, Expenses and Other Cost of sales 3,540 3,926 4,024 4,264 3,911 16,126 -10% Selling, general and administrative 2,483 2,479 2,702 2,519 2,804 10,504 0% Research and development 3,992 4,276 13,321 3,307 9,628 30,531 -7% Restructuring costs 123 67 151 126 255 599 84% Other (income) expense, net (33) 89 172 126 78 466 * Income (Loss) Before Taxes 5,670 3,650 (5,335) 5,620 (2,046) 1,889 55% Income Tax Provision (Benefit) 903 825 637 870 (821) 1,512 Net Income (Loss) 4,767 2,825 (5,972) 4,750 (1,225) 377 69% Less: Net Income Attributable to Noncontrolling Interests 5 4 3 5 1 12 Net Income (Loss) Attributable to Merck & Co., Inc. 4,762 $ 2,821 $ (5,975) $ 4,745 $ (1,226) $ 365 $ 69% Earnings (Loss) per Common Share Assuming Dilution (1) 1.87 $ 1.11 $ (2.35) $ 1.86 $ (0.48) $ 0.14 $ 68% Average Shares Outstanding Assuming Dilution (1) 2,544 2,551 2,539 2,546 2,533 2,547 Tax Rate 15.9% 22.6% -11.9% 15.5% 40.1% 80.0% * 100% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. Table 1a MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) % Change 1Q (1) Because the company recorded a net loss in the second and fourth quarters of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. 2024 1Q 1Q 2Q 3Q 4Q Full Year 2023 2 -- 3 of 9 -- First Quarter Cost of sales 3,540 $ 463 116 579 2,961 $ Selling, general and administrative 2,483 21 5 26 2,457 Research and development 3,992 16 2 18 3,974 Restructuring costs 123 123 123 – Other (income) expense, net (33) (4) (116) (120) 87 Income Before Taxes 5,670 (496) (246) 116 (626) 6,296 Income Tax Provision (Benefit) 903 (92) (3) (42) (3) 25 (3) (109) 1,012 Net Income 4,767 (404) (204) 91 (517) 5,284 Net Income Attributable to Merck & Co., Inc. 4,762 (404) (204) 91 (517) 5,279 Earnings per Common Share Assuming Dilution 1.87 $ (0.16) (0.08) 0.04 (0.20) 2.07 $ Tax Rate 15.9% 16.1% Only the line items that are affected by non-GAAP adjustments are shown. MERCK & CO., INC. FIRST QUARTER 2024 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Table 2a (3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Adjustment Subtotal Non-GAAP Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect the amortization of intangible assets. Amounts included in other (income) expense, net, primarily reflect royalty income related to the prior termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. 3 -- 4 of 9 -- First Quarter Cost of sales 3,926 $ 545 29 574 3,352 $ Selling, general and administrative 2,479 20 1 21 2,458 Research and development 4,276 10 10 4,266 Restructuring costs 67 67 67 - Other (income) expense, net 89 15 (429) 573 (3) 159 (70) Income Before Taxes 3,650 (590) (97) 429 (573) (831) 4,481 Income Tax Provision (Benefit) 825 (105) (4) (18) (4) 95 (4) (60) (4) (88) 913 Net Income 2,825 (485) (79) 334 (513) (743) 3,568 Net Income Attributable to Merck & Co., Inc. 2,821 (485) (79) 334 (513) (743) 3,564 Earnings per Common Share Assuming Dilution 1.11 $ (0.19) (0.03) 0.13 (0.20) (0.29) 1.40 $ Tax Rate 22.6% 20.4% Only the line items that are affected by non-GAAP adjustments are shown. GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Certain Other Items MERCK & CO., INC. FIRST QUARTER 2023 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2b (3) Reflects a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation. (4) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Adjustment Subtotal Non-GAAP Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect the amortization of intangible assets. Amounts included in other (income) expense, net, reflect a $37 million loss on the sale of a business and an increase in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture, partially offset by royalty income. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. 4 -- 5 of 9 -- MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3 2024 2023 1Q 1Q 1Q 2Q 3Q 4Q Full Year Nom % Ex-Exch % TOTAL SALES (1) $15,775 $14,487 $15,035 $15,962 $14,630 $60,115 9 12 PHARMACEUTICAL 14,006 12,721 13,457 14,263 13,141 53,583 10 13 Oncology Keytruda 6,947 5,795 6,271 6,338 6,608 25,011 20 24 Alliance Revenue – Lynparza (2) 292 275 310 299 315 1,199 6 7 Alliance Revenue – Lenvima (2) 255 232 242 260 226 960 10 10 Welireg 85 42 50 54 72 218 102 102 Alliance Revenue – Reblozyl (3) 71 43 47 52 70 212 66 66 Vaccines (4) Gardasil/Gardasil 9 2,249 1,972 2,458 2,585 1,871 8,886 14 17 ProQuad/M-M-R II/Varivax 570 528 582 713 545 2,368 8 8 Vaxneuvance 219 106 168 214 176 665 106 106 RotaTeq 216 297 131 156 185 769 -27 -27 Pneumovax 23 61 96 92 140 85 412 -36 -33 Hospital Acute Care Bridion 440 487 502 424 429 1,842 -10 -8 Prevymis 174 129 143 157 175 605 35 39 Dificid 73 65 76 74 87 302 12 12 Zerbaxa 56 50 54 53 61 218 13 15 Noxafil 56 60 55 51 46 213 -7 4 Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 98 99 68 92 108 367 -1 -1 Adempas (6) 70 59 65 65 66 255 18 18 Virology Lagevrio 350 392 203 640 193 1,428 -11 -5 Isentress/Isentress HD 111 123 136 119 105 483 -10 -7 Delstrigo 56 44 50 54 54 201 28 30 Pifeltro 42 34 38 37 33 142 23 23 Neuroscience Belsomra 46 56 63 58 54 231 -17 -11 Immunology Simponi 184 180 180 179 171 710 2 1 Remicade 39 51 48 45 43 187 -24 -21 Diabetes (7) Januvia 419 551 511 581 547 2,189 -24 -21 Janumet 251 329 354 255 240 1,177 -24 -20 Other Pharmaceutical (8) 576 626 560 568 576 2,333 -8 -6 ANIMAL HEALTH 1,511 1,491 1,456 1,400 1,278 5,625 1 4 Livestock 850 849 807 874 808 3,337 - 4 Companion Animal 661 642 649 526 470 2,288 3 4 Other Revenues (9) 258 275 122 299 211 907 -6 11 *200% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $3,424 million in the first quarter of 2024 and $3,133 million in the first quarter 2023. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (6) Net product sales in Merck's marketing territories. (7) Total Diabetes sales were $745 million in the first quarter of 2024 and $950 million in the first quarter of 2023. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were$61 million in the first quarter of 2024 and $51 million in the first quarter of 2023. 5 -- 6 of 9 -- MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES FIRST QUARTER 2024 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3a Global U.S. International 1Q 2024 1Q 2023 % Change 1Q 2024 1Q 2023 % Change 1Q 2024 1Q 2023 % Change TOTAL SALES (1) $15,775 $14,487 9 $7,478 $6,659 12 $8,297 $7,828 6 PHARMACEUTICAL 14,006 12,721 10 6,936 6,117 13 7,070 6,604 7 Oncology Keytruda 6,947 5,795 20 4,119 3,485 18 2,828 2,310 22 Alliance Revenue – Lynparza (2) 292 275 6 135 142 -4 157 133 18 Alliance Revenue – Lenvima (2) 255 232 10 173 153 13 82 79 3 Welireg 85 42 102 77 41 89 7 1 * Alliance Revenue – Reblozyl (3) 71 43 66 58 30 93 12 12 - Vaccines (4) Gardasil/Gardasil 9 2,249 1,972 14 488 416 17 1,761 1,556 13 ProQuad/M-M-R II/Varivax 570 528 8 438 421 4 133 107 24 Vaxneuvance 219 106 106 161 94 72 58 13 * RotaTeq 216 297 -27 149 180 -17 67 117 -43 Pneumovax 23 61 96 -36 6 40 -85 55 56 -1 Hospital Acute Care Bridion 440 487 -10 329 276 19 111 210 -47 Prevymis 174 129 35 74 54 37 100 75 33 Dificid 73 65 12 68 62 10 5 3 49 Zerbaxa 56 50 13 33 27 23 23 23 1 Noxafil 56 60 -7 8 14 -43 48 46 4 Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 98 99 -1 90 83 8 8 16 -51 Adempas (6) 70 59 18 70 59 18 Virology Lagevrio 350 392 -11 45 -2 * 305 394 -23 Isentress/Isentress HD 111 123 -10 50 52 -3 61 71 -14 Delstrigo 56 44 28 12 11 9 44 33 34 Pifeltro 42 34 23 29 24 22 13 10 25 Neuroscience Belsomra 46 56 -17 15 16 -9 32 40 -21 Immunology Simponi 184 180 2 184 180 2 Remicade 39 51 -24 39 51 -24 Diabetes (7) Januvia 419 551 -24 183 271 -32 236 280 -16 Janumet 251 329 -24 39 56 -32 212 272 -22 Other Pharmaceutical (8) 576 626 -8 157 171 -8 419 457 -8 ANIMAL HEALTH 1,511 1,491 1 474 482 -2 1,037 1,010 3 Livestock 850 849 - 166 174 -5 683 676 1 Companion Animal 661 642 3 308 308 - 354 334 6 Other Revenues (9) 258 275 -6 68 60 13 190 214 -11 *200% or greater (6) Net product sales in Merck's marketing territories. (7) Total Diabetes sales were $745 million in the first quarter of 2024 and $950 million in the first quarter of 2023. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $61 million in the first quarter of 2024 and $51 million in the first quarter of 2023. Sum of U.S. plus international may not equal global due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $3,424 million in the first quarter of 2024 and $3,133 million in the first quarter 2023. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. 6 -- 7 of 9 -- MERCK & CO., INC. PHARMACEUTICAL GEOGRAPHIC SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3b 2024 2023 % Change 1Q 1Q 2Q 3Q 4Q Full Year 1Q TOTAL PHARMACEUTICAL $14,006 $12,721 $13,457 $14,263 $13,141 $53,583 10 United States 6,936 6,117 6,570 7,153 6,698 26,539 13 % Pharmaceutical Sales 49.5% 48.1% 48.8% 50.1% 51.0% 49.5% Europe (1) 2,555 2,326 2,401 2,497 2,491 9,715 10 % Pharmaceutical Sales 18.2% 18.3% 17.8% 17.5% 19.0% 18.1% China 1,744 1,694 1,887 1,674 1,456 6,710 3 % Pharmaceutical Sales 12.5% 13.3% 14.0% 11.7% 11.1% 12.5% Japan 802 737 652 1,062 629 3,081 9 % Pharmaceutical Sales 5.7% 5.8% 4.8% 7.4% 4.8% 5.7% Latin America 601 470 566 696 596 2,328 28 % Pharmaceutical Sales 4.3% 3.7% 4.2% 4.9% 4.5% 4.3% Asia Pacific (other than China and Japan) 580 703 705 636 616 2,661 -18 % Pharmaceutical Sales 4.1% 5.5% 5.2% 4.5% 4.7% 5.0% Eastern Europe/Middle East/Africa 395 381 370 301 299 1,351 3 % Pharmaceutical Sales 2.8% 3.0% 2.7% 2.1% 2.3% 2.5% Canada 138 141 127 133 138 540 -2 % Pharmaceutical Sales 1.0% 1.1% 0.9% 0.9% 1.1% 1.0% Other 255 152 179 111 218 658 68 % Pharmaceutical Sales 1.9% 1.2% 1.6% 0.9% 1.5% 1.4% Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom. 7 -- 8 of 9 -- OTHER (INCOME) EXPENSE, NET 1Q24 1Q23 Interest income (73) $ (112) $ Interest expense 303 242 Exchange losses 83 61 Income from investments in equity securities, net (1) (143) (450) Net periodic defined benefit plan (credit) cost other than service cost (160) (115) Other, net (43) 463 Total (33) $ 89 $ (1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. MERCK & CO., INC. OTHER (INCOME) EXPENSE, NET - GAAP (AMOUNTS IN MILLIONS) (UNAUDITED) Table 4 8 -- 9 of 9 --